Terumo (OTCPK:TRUM.Y) FY Conference January 12, 2026 08:15 PM ET Company ParticipantsJin Hagimoto - CFOHikaru Samejima - CEOConference Call ParticipantsNone - AnalystOperatorGood evening. Thank you for joining us. I'm Naoki Sato from J.P. Morgan. Welcome to J.P. Morgan Healthcare Conference, Terumo's presentation. Again, it's my pleasure to be introducing Terumo. From the company, we have CEO Hikaru Samejima for the presentation, and after that, we'll have a Q&A session. With that, I will pass on to Mr. Sam ...

The biotechnology sector offers investors a high-risk, high-reward opportunity as companies race to bring breakthrough therapies to market. Here are three standout stocks that should be on your watchlist in 2026, according to Barchart ratings. Each of these three biotech stocks offers varying risk profiles and development timelines for investors willing to bet on medical innovation. More News from Barchart Best High-Risk Biotech Stocks for 2026 #1: Ligand Pharmaceuticals (LGND) Ligand Pharmaceuticals ...

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of Novo Nordisk. ...

TUCSON, Ariz., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of Directors of the Arizona Bioindustry Association (AZBio), the state aff ...

海南省人民医院观澜湖院区开诊 规划床位1000张 海南日报海口12月15日讯(海南日报全媒体记者 马珂)12月15日，海南省人民医院观澜湖院区正式 开诊。 据了解，观澜湖院区是立足优化省会三级医院布局，惠及百姓民生的重点项目。该院区坐落于海口 市龙华区星影大道7号，紧邻G98海南环线高速龙桥互通，距高速路口仅1.5公里，规划床位1000张，服 务范围涵盖海口南部片区，将满足各市县赴海口就医的患者及境内外游客、投资者的健康需求。 "没想到在海南就能看到北京、上海等医院的大专家，这真是实实在在的福利!"当天，来自儋州的 王先生带着父亲的影像资料候诊。 为普惠于民，海南省人民医院观澜湖院区在开业初期实行门诊挂号费全免政策，开诊首日即放出 445个免费号源。目前，首批开放了包括心血管内科、神经内科、神经外科、消化内科、妇科、儿科等 在内的21个临床专科门诊，并配备心电图、彩超、DR等检查项目，以及抽血等各类检验检查项目，可 满足绝大部分常见病、多发病及部分疑难病的门诊诊疗需求。 观澜湖院区将与省医院秀英主院区定位差异化，形成互补型发展关系，将按照"强专科，优综合"的 学科发展战略，建设急危重症诊疗中心，精准医学诊疗平 ...

QIONGHAI, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The 1st Global Innovative Pharmaceutical and Medical Device Expo and the 4th International Conference on Real-World Studies of Medical Products were held in Boao Lecheng International Medical Tourism Pilot Zone in recent days. The events showcased over 100 types of cutting-edge international pharmaceuticals and medical devices and brought together about 1,000 leading figures from government, industry, academia, and research to explore the latest breakthroug ...

London, UK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals is pleased to announce the appointment of Dr. Vignesh Rajah as its Chief Medical Officer (CMO). Dr. Rajah brings over two decades of global experience leading medical and clinical organisations in US and European pharmaceutical and biotech companies.  This strategic appointment marks a significant milestone in SERB’s growth journey. As CMO, Dr. Rajah will play a pivotal role in advancing the company’s scientific and medical capabilities, sup ...

Core Insights - Penumbra, Inc. is a key player in the medical device industry, focusing on innovative solutions for neuro and vascular conditions, particularly in stroke treatment [1] - Evercore ISI has reaffirmed its "Outperform" rating for Penumbra, adjusting the price target from $285 to $286, reflecting confidence in the company's growth potential [2][6] - Institutional interest in Penumbra is increasing, with significant investments from firms like Spire Wealth Management and First Horizon Advisors Inc., indicating strong confidence in the company's future performance [3][6] Stock Performance - Penumbra's stock has experienced a notable increase of 16.89%, translating to a rise of $38.09, with a trading range today between $261.17 and $272 [4][6] - Over the past year, the stock has fluctuated significantly, reaching a high of $310 and a low of $221.26, showcasing its volatility and growth potential [4] - The current stock price is $263.62, showing a slight decrease but remaining within a healthy range [2] Market Position - Penumbra has a market capitalization of approximately $10.28 billion and a trading volume of 684,099 shares, underscoring its significance in the medical device industry [5] - The company's ability to attract institutional investors and maintain a strong market presence highlights its potential for continued success [5]

Core Viewpoint - Sonoma Pharmaceuticals, Inc. is set to showcase its patented Microcyn® technology-based products at MEDICA 2025, highlighting its leadership in the healthcare sector [1] Company Summary - Sonoma Pharmaceuticals specializes in developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care [1] Industry Summary - MEDICA 2025 is one of the largest and most prestigious medical B2B trade fairs globally, expected to attract 80,000 visitors from 72 countries and over 5,000 exhibitors [1]

Core Points - MannKind Corporation, in partnership with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship to honor the legacy of its founder Alfred E. Mann, distributing $100,000 in scholarship funds to support young adults living with diabetes pursuing higher education in life sciences [1][2][8] - The scholarship program aims to empower students aged 18-22 with type 1 or type 2 diabetes, providing up to $10,000 per recipient, distributed in annual installments of $2,500 [3][4] - The initiative reflects Alfred E. Mann's commitment to improving human life through medical advancement and philanthropy, continuing his vision of giving back to the community [2][5] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [6][7] - The company has a history of developing breakthrough medical devices and treatments, including the inhaled insulin product Afrezza, which was brought to market with a significant investment of nearly $1 billion by Alfred E. Mann [5][6] Partnership and Community Impact - The partnership with The Diabetes Link aims to expand access to higher education for young adults with diabetes, addressing the rising costs of college and easing financial burdens [5][12] - The Diabetes Link is a national nonprofit organization dedicated to empowering young adults living with diabetes through peer support and resources, envisioning a future where they thrive in their personal and professional lives [12]